Social•Apr 21, 2026
First Trial Shows Best‑in‑Class NLRP3 Inhibitor Promise
Excited to complete our first clinical trial for BGE-102. Clinical data supporting best-in-class potential, built on new chemistry and a novel binding site targeting NLRP3 - a central driver of of chronic inflammation in aging. On to Phase 2!
By Kristen Fortney